• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Atomoxetine (marketed as Strattera) Information

Atomoxine (marketed as Strattera) is currently approved in the United States to treat attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. 


This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA intends to update this page when additional information or analyses become available 


Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.

 

-

Labeling and Regulatory History from Drugs@FDA

-
 

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857